Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.9650
+0.0020 (0.21%)
At close: Sep 18, 2026, 4:00 PM EDT
0.9701
+0.0051 (0.53%)
After-hours: Sep 18, 2026, 7:42 PM EDT
Werewolf Therapeutics Revenue
Werewolf Therapeutics had revenue of $21.00M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $21.00M.
Revenue (ttm)
$21.00M
Revenue Growth
n/a
P/S Ratio
2.23
Revenue / Employee
$1,500,000
Employees
14
Market Cap
46.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.89M | -18.06M | -90.55% |
| Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
| Dec 31, 2022 | 16.40M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 13.79M |
| Metagenomi Therapeutics | 13.56M |
| Apollomics | 8.84M |
| Mereo BioPharma Group | 500.00K |
| Clene | 197.00K |
HOWL News
- 10 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX) - GlobeNewsWire
- 26 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ) - GlobeNewsWire
- 4 weeks ago - Why Werewolf Therapeutics stock exploded higher and what comes next? - Invezz
- 4 weeks ago - Why Is Penny Stock Werewolf Therapeutics (HOWL) Up Today? - TipRanks
- 4 weeks ago - Werewolf Therapeutics, Ambros Therapeutics to combine in all-stock transaction - TheFly
- 4 weeks ago - Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement - GlobeNewsWire
- 7 weeks ago - Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 7 weeks ago - Werewolf Therapeutics Quarterly report: Q2 2026 - Filings